# Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

> **NCT00504972** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 23 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** hLL1

## Key facts

- **NCT ID:** NCT00504972
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-04-01
- **Final completion:** 2015-10-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504972, "Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00504972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*